New strain Brevibacillus laterosporus TSA31-5 produces both brevicidine and brevibacillin, exhibiting distinct antibacterial modes of action against Gram-negative and Gram-positive bacteria

• Published in: PloS one 2024-04, Vol.19 (4), p.e0294474-e0294474
• Main Authors: Kim, Jeongeun, Kim, Jueun, Yun, Hyosuk, Ganbaatar, Byambasuren, Tahmasebi, Aminallah, Seo, Sun Il, Kim, Pyoung Il, Lee, Chul Won
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - chemistry; Anti-Infective Agents - pharmacology; Bacillus; Biology and Life Sciences; Brevibacillus; Gram-Negative Bacteria; Gram-Positive Bacteria; Medicine and Health Sciences; Microbial Sensitivity Tests; Research and Analysis Methods; Tandem Mass Spectrometry
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0294474

The growing prevalence of antibiotic resistance has made it imperative to search for new antimicrobial compounds derived from natural products. In the present study, Brevibacillus laterosporus TSA31-5, isolated from red clay soil, was chosen as the subject for conducting additional antibacterial investigations. The fractions exhibiting the highest antibacterial activity (30% acetonitrile eluent from solid phase extraction) were purified through RP-HPLC. Notably, two compounds (A and B) displayed the most potent antibacterial activity against both Escherichia coli and Staphylococcus aureus. ESI-MS/MS spectroscopy and NMR analysis confirmed that compound A corresponds to brevicidine and compound B to brevibacillin. Particularly, brevicidine displayed notable antibacterial activity against Gram-negative bacteria, with a minimum inhibitory concentration (MIC) range of 1-8 μg/mL. On the other hand, brevibacillin exhibited robust antimicrobial effectiveness against both Gram-positive bacterial strains (MIC range of 2-4 μg/mL) and Gram-negative bacteria (MIC range of 4-64 μg/mL). Scanning electron microscopy analysis and fluorescence assays uncovered distinctive morphological alterations in bacterial cell membranes induced by brevicidine and brevibacillin. These observations imply distinct mechanisms of antibacterial activity exhibited by the peptides. Brevicidine exhibited no hemolysis or cytotoxicity up to 512 μg/mL, comparable to the negative control. This suggests its promising therapeutic potential in treating infectious diseases. Conversely, brevibacillin demonstrated elevated cytotoxicity in in vitro assays. Nonetheless, owing to its noteworthy antimicrobial activity against pathogenic bacteria, brevibacillin could still be explored as a promising antimicrobial agent.